Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
$6.51
-$0.34(-1.95%)
At close: 4:00 PM EST
$6.51
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.98 - $16.62
Previous CloseN/A
Volume45.37K
Average Volume (3M)230.28K
Market Cap
$174.96M
Enterprise Value$59.16M
Total Cash (Recent Filing)$125.14M
Total Debt (Recent Filing)$12.68M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
May 07, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding26,509,024
10 Day Avg. Volume434,948
30 Day Avg. Volume230,275
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue21.15
Enterprise Value/Gross Profit-5.92
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$34.00Price Target Upside422.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.42
Revenue Forecast (FY)$672.57K
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe AURORA pivotal study was designed based on strong mid-stage results, lowering late-stage program risk and raising the probability of a successful outcome.
Commercial Access And CostMRNA-based Descartes-08 does not require lymphodepletion and can be given in outpatient settings, lowering treatment complexity and projected costs while supporting broader adoption outside specialty centers.
Regulatory And Pipeline ExpansionFDA acceptance of an IND for myositis and initiation of a pediatric basket study enable potential pivotal trials and broaden the development pathway into additional autoimmune and pediatric indications.
Bears Say
Commercial Uptake And ReimbursementPersistent safety concerns for T-cell engaging therapies could reduce payer willingness to provide reimbursement and constrain commercial uptake of related candidates in the company's pipeline.
Regulatory OversightSevere infections and neurotoxicity associated with T-cell engager classes may prompt stricter regulatory requirements and added trial monitoring, increasing development timelines and costs.
Safety RisksCompany-identified risks of cytokine release syndrome and immune-cell associated neurotoxicity with T-cell engagers could limit advancement and investor confidence in those programs.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.98 and its highest was $16.62 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $174.96M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 44 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on Mar 09, 2026. The company reported -$3.46 earnings per share for the quarter, missing the consensus estimate of -$0.851 by -$2.609.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 26,509,024 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of -$3.46 in its last earnings report, missing expectations of -$0.851. Following the earnings report the stock price went up 31.679%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (422.27% Upside)
$34.00 (422.27% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $258.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Company Description
Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$34.00
▲(422.27% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
41.38% Insiders
8.72% Mutual Funds
3.50% Other Institutional Investors
43.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---